What is Novo 7 used for?

What is Novo 7 used for?

This medication is used to treat and prevent bleeding in people with certain conditions (such as hemophilia type A or B, low levels of factor VII, Glanzmann’s thrombasthenia).

Is NovoSeven a blood product?

No human serum or other proteins are used in the production or formulation of NovoSeven. NovoSeven is supplied as a sterile, white lyophilized powder of rFVIIa in single-use vials….NovoSeven®

Contents sodium chloride*
1.2 mg (60 KIU) Vial 5.84 mg
2.4 mg (120 KIU) Vial 11.68 mg
4.8 mg (240 KIU) Vial 23.36 mg

What is Factor VII deficiency?

Factor VII deficiency is a rare genetic bleeding disorder characterized by a deficiency or reduced activity of clotting factor VII. Clotting factors are specialized proteins that are essential for the blood to clot normally.

What is the difference between NovoSeven and NovoSeven RT?

The new NovoSeven RT provides the same safety and efficacy as the original NovoSeven(R)-but it can be transported and administered quickly.” NovoSeven RT has been manufactured to be room temperature stable (from 36 degrees F to 77 degrees F outside a refrigerator).

When should I take NovoSeven?

Keep NovoSeven® RT on hand to treat as soon as possible after a bleeding episode starts. Get an overview of doses for bleeds and perioperative management for each indication.

Is NovoSeven a bypassing agent?

NovoSeven® RT means speed, effectiveness and portability. It’s a recombinant bypassing agent that you infuse on-demand, and has a long history of helping people control their bleeds.

What is NovoSeven made of?

NovoSeven is a novel product and contains activated recombinant DNA human coagulation factor VII (rFVIIa). The recombinant molecule is produced in baby hamster kidney (BHK) cells. Recombinant FVIIa is almost identical to human plasma FVIIa except for a difference in glycosylation.

Is NovoSeven FDA approved?

PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ — Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative management in patients with Glanzmann’s Thrombasthenia (GT) …

Can factor 7 deficiency be cured?

‌Factor VII deficiency can be treated using these clotting agents, which promote blood clotting and prevent bleeding: Recombinant factor VIIa. This is a replacement therapy to help increase the levels of factor VII in your body.

How is factor 7 deficiency diagnosed?

Diagnosis is made through activated partial thromboplastin time (aPTT) test and prothrombin time (PT) test. Diagnosis can be confirmed with a FVII assay. Acquired factor VII deficiency can occur in patients with liver disease and vitamin K deficiency, and in those taking oral anticoagulants.

How expensive is NovoSeven?

The cost for NovoSeven RT intravenous powder for injection (1000 mcg (1 mg)) is around $2,515 for a supply of 1000 powder for injection, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.

What kind of CPU does the Novo 7 use?

Unlike most competing tablets, the Novo 7 Basic used a MIPS based CPU (1 GHz Ingenic JZ4770 XBurst), while the Advanced had a more common ARM CPU. Both had 800×480 pixel touch screens and were launched with Android 2.2, although the company later released updates to Android 3 and Android 4.

When does the Novo 7 crystal come out?

In September 2012, Ainol announced the release of the Novo 7 Crystal with the latest Android 4.1.1 Jelly Bean. The tablet is set to be made available, for shipment, on 28 September. Novo7 Crystal matches and surpasses the specifications of the Novo 7 Elf II and looks to replace its predecessor.

Who is the manufacturer of the NOVO7 tablet computer?

The NOVO7 is a series of Android tablet computers manufactured by the Chinese company Ainol Electronics.

How much NovoSeven is needed for congenital factor VII deficiency?

Congenital Factor VII deficiency. Since the mean plasma recovery for NovoSeven (coagulation factor viia (recombinant)) is 20% for FVII-deficient patients, a NovoSeven (coagulation factor viia (recombinant)) dose range of 16-27 μg/kg would be required to achieve sufficient FVII plasma levels for hemostasis.